Consistent with previous reports indicating that treatment with HDACis or PARPis can upregulate the immune checkpoint ligand PD‐L1 in tumor cells,[15, 22, 38] P2 treatment markedly increased PD‐L1 expression at the mRNA and protein levels in a dose‐dependent manner (Figure5A,B). Here, CD274 is linked to neoplasm.